Standard and reduced high-dose volume radiation therapy for muscle-invasive bladder cancer provide comparable tumor control and decreased late toxicity when compared to surgery, according to a study published in the October 1, 2013 print edition of the International Journal of Radiation Oncology ● Biology ● Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO). The research is part of the United Kingdom’s BC2001 clinical trial, one of the largest randomized trials conducted involving radiation therapy (RT) in patients with muscle-invasive bladder cancer.
Cystectomy (partial or whole bladder removal surgery) is often the standard treatment for patients with muscle-invasive bladder cancer; however, advanced RT techniques that spare the bladder may be an effective alternative for patients who are unsuitable for or unwilling to undergo cystectomy. This research was conducted to determine if some of the drawbacks of RT of the bladder, such as local recurrence and late toxicity risks, could be reduced with a lower dose of RT being delivered to the areas of the bladder outside of the tumor region, and to assess the tumor control and toxicity of RT.
This phase III randomized trial was sponsored by the University of Birmingham, UK, supported by Cancer Research UK, and facilitated by the National Institute for Health Research Cancer Research Network.
The cohort of participants for this portion of the trial included 219 patients from 28 centers across the United Kingdom who received either standard radiation therapy or reduced high-volume radiation therapy. Patients were all age 18 and older and had stage T2 - T4a bladder cancer. Study participants were randomized—108 received standard whole bladder radiation therapy (sRT) and the remaining 111 patients received reduced high-dose volume radiation therapy (RHDVRT), in which the full radiation dose was delivered to the tumor and 80 percent of the maximum dose was delivered to the uninvolved bladder. [360 patients in the BC2001 trial were also randomly assigned to receive radiation therapy alone or radiation therapy plus chemotherapy in a partial 2 x 2 factorial design; the results of the chemoradiation portion of the trial are not included in this manuscript.]
Study participants received RT doses based on their cancer center’s choice of either 55 Gy/20 fractions over 4 weeks or 64 Gy/32 fractions over 6.5 weeks. For patients in the sRT group, the planning target volume (PTV) was the outer bladder wall, plus the extravesical extent of the tumor with a 1.5 cm margin. For patients in the RHDVRT group, two PTVs were defined: PTV1, as in the sRT group, and PTV2, as the gross tumor volume plus a 1.5 cm margin.
Patients were assessed weekly throughout treatment for toxicity; and side effects were measured at six, nine and 12 months post-treatment, and annually thereafter. Additionally, tumor control was assessed at six, nine and 12 months after treatment and then annually for up to five years. The median patient follow-up time was 72.7 months post-treatment.
In this radiation therapy volume comparison of the study, the primary endpoints of interest were late toxicity and local control. Late toxicity was determined in this study to be radiation therapy-related side effects at least one to two years post-treatment. The Radiation Therapy Oncology Group (RTOG) scale and Late Effects of Normal Tissue (Subjective, Objective, Management) (LENT/SOM) scale were utilized to measure late toxicity in study participants. Rates of late toxicity were lower than anticipated, and the number of patients reporting RTOG or LENT/SOM toxicities (side effects) was not significantly different between the sRT and RHDVRT groups. The overall cumulative Grades 3/4 RTOG toxicity rate was 13 percent at two years post-treatment, and the percentage of patients with Grades 3/4 toxicity at any specific point was shown to be
< 8 percent throughout in both groups.
Two-year locoregional recurrence free (LRRF) rate was 61 percent for the sRT group and 64 percent for the RHDVRT group, but non-inferiority of locoregional control (proof that the RHDVRT treatment was at least not appreciably inferior than the sRT treatment) could not be formally determined in the study.
“We have now demonstrated that delivering at least 75 percent of the dose [of RT] to the uninvolved bladder is deliverable across multiple sites without obvious detriment to local disease control or survival, although non-inferiority could not be formally confirmed,” said lead author Robert A. Huddart, PhD, of The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust. “These results confirm, however, that RT is an effective alternative for patients unable to undergo cystectomy. Further study using image-guided treatment with or without dose escalation is now also warranted.”
ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologist, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology•Biology•Physics (http://www.redjournal.org) and Practical Radiation Oncology (http://www.practicalradonc.org); developed and maintains an extensive patient website, http://www.rtanswers.org; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.
Fairfax, Va., October 9, 2013